Tango Therapeutics TNGX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -206.2%-27.8pp | -178.4%-12.5pp | -165.9%+481pp | -647.3%-291pp | -355.9%-9.8pp | |
| Net margin | -188.2%-25.3pp | -162.9%-11.7pp | -151.1%+448pp | -599.1%-276pp | -322.7%-12.9pp | |
| Returns | ||||||
| Return on equity | -38.4%-1.2pp | -37.2%+14.4pp | -51.7%+24.4pp | -76.1%-14.7pp | -61.3%-3.8pp | |
| Return on invested capital | -57.7%-6.5pp | -51.3%+12.7pp | -64%+23.5pp | -87.5%-11.1pp | -76.4%-1.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×-0.1× | 0.2×+0.2× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 27.4×+11.1× | 16.3×+7.4× | 8.9×+4.1× | 4.7×-1.5× | 6.3×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.3×0.0× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $2.73-8.5% | $2.98+119% | $1.36+11.3% | $1.22-19.2% | $1.51-17.2% | |
| Valuation | ||||||
| Market capitalization | $2.99B+150% | $1.19B+27.7% | $934.59M+60.9% | $580.99M+292% | $148.11M-55.4% | |
| Price / sales | 52.4×+33.2× | 19.1×+5.1× | 14.1×-9.9× | 23.9×+20.3× | 3.6×-4.3× | |
| Price / book | 7.6×+4.2× | 3.4×-2.4× | 5.8×+1.5× | 4.3×+3.4× | 0.9×-0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tango Therapeutics's ratios come from?
- Every ratio is computed from Tango Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
